Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer

Cancer Genetics and Cytogenetics

Volumn 199, Issue 1, 2010, Pages 24-30

  Silva Soares, Emerson Wander ^a   de Lima Santos, Savana Camilo ^b   Bueno, Alexandre Galvão ^c   Cavalli, Iglenir João ^b   Cavalli, Luciane Regina ^d   Fouto Matias, Jorge Eduardo ^b   de Souza Fonseca Ribeiro, Enilze Maria ^b  

^a UOPECCAN ^*  (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c UOPECCAN   (Brazil)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; FRAGILE HISTIDINE TRIAD PROTEIN; HORMONE RECEPTOR; TAMOXIFEN; ACID ANHYDRIDE HYDROLASE; MICROSATELLITE DNA; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; GENE LOCUS; HAZARD RATIO; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROSATELLITE MARKER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL TIME; BREAST TUMOR; FEMALE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC LOCI; HUMANS; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; MICROSATELLITE REPEATS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 77951904177     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.01.019     Document Type: Article

References (29)

1. Singletary S.E., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., Borgen P.I., Clark G., Edge S.B., Hayes D.F., Hughes L.L., Hutter R.V., Morrow M., Page D.L., Recht A., Theriault R.L., Thor A., Weaver D.L., Wieand H.S., Greene F.L. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636.
2. Radford D.M., Phillips N.J., Fair K.L., Ritter J.H., Holt M., Donis-Keller H. Allelic loss and progression of breast cancer [Erratum in: Cancer Res 1996;56:935]. Cancer Res 1995, 55:5180-5183.
3. Silva J.M., Gonzalez R., Provencio M., Dominguez G., Garcia J.M., Gallego I., Palacios J., España P., Bonilla F. Loss of heterozygosity in BRCA1 and BRCA2 markers and high-grade malignancy in breast cancer. Breast Cancer Res Treat 1999, 53:9-17.
4. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823.
5. Miyakis S., Spandidos D. Allelic loss in breast cancer. Cancer Detect Prev 2002, 26:426-434.
6. Hanby A.M., Kelsell D.P., Potts H.W., Gillett C.E., Bishop D.T., Spurr N.K., Barnes D.M. Association between loss of heterozygosity of the BRCA1 and BRCA2 and morphological attributes of sporadic breast cancer. Int J Cancer 2000, 88:204-208.
7. Johnson S.M., Shaw J.A., Walker R.A. Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1, and BRCA2. Int J Cancer 2002, 98:205-209.
8. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999, 59:3866-3869.
9. Ingvarsson S., Sigbjornsdottir B.I., Huiping C., Jonasson J.G., Agnarsson B.A. Alterations of the FHIT gene in breast cancer: association with tumor progression an patients survival. Cancer Detect Prev 2001, 25:292-298.
10. Kinzler K.W., Vogelstein B. Cancer-susceptibility genes: gatekeepers and caretakers. Nature 1997, 386(761):763.
11. Breivik J. The evolutionary origin of genetic instability in cancer development. Semin Cancer Biol 2005, 15:51-60.
12. Wooster R., Weber B.L. Breast and ovarian cancer. N Engl J Med 2003, 348:2339-2347.
13. Beckmann M.W., Picard F., An H.X., van Roeyen C.R., Dominik S.I., Mosny D.S., Schnürch H.G., Bender H.G., Niederacher D. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br J Cancer 1996, 73:1220-1226.
14. Rosen E.M., Fan S., Pestell R.G., Goldberg I.D. BRCA1 gene in breast cancer. J Cell Physiol 2003, 196:19-41.
15. Birgisdottir V., Stefansson O.A., Bodvarsdottir S.K., Hilmarsdottir H., Jonasson J.G., Eyfjord J.E. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006, 8:38-48.
16. Mueller C.R., Roskelley C.D. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 2003, 5:45-52.
17. Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., Tornielli S., Pilotti S., De Gregorio L., Pastorino U., Pierotti M.A., Ohta M., Huebner K., Croce C.M. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 1996, 85:17-26.
18. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84:587-597.
19. Santos S.C., Cavalli L.R., Cavalli I.J., Lima R.S., Haddad B.R., Ribeiro E.M. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil. J Clin Pathol 2004, 57:374-377.
20. Huebner K., Croce C.M. Cancer and the FRA3B/ FHIT fragile locus: it's a HIT. Br J Cancer 2003, 88:1501-1506.
21. Goldhirsch A., Glick J.H., Gelber R.D., Senn H.J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998, 90:1601-1608.
22. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
23. Rosen P.P. Tumor emboli in intramammary lymphatics in breast carcinoma: pathologic criteria for diagnosis and clinical significance. Pathol Annu 1983, 18:215-232.
24. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
25. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
26. Cawkwell L., Bell S.M., Lewis F.A., Dixon M.F., Taylor G.R., Quirke P. Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 1993, 67:1262-1267.
27. Thompson M.E., Jensen R.A., Obermiller P.S., Page D.L., Holt J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995, 9:444-450.
28. Gatalica Z., Lele S.M., Rampy B.A., Norris B.A. The expression of FHIT is related inversely to disease progression in patients with breast carcinoma. Cancer 2000, 88:1378-1383.
29. Turner B.C., Ottey M., Zimonjic D.B., Potoczek M., Hauck W.W., Pequignot E., Keck-Waggoner C.L., Sevignani C., Aldaz C.M., McCue P.A., Palazzo J., Huebner K., Popescu N.C. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res 2002, 62:4054-4060.